Utah is currently home to 1208 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
NCT05987189
Recruiting
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
01/12/2024
Locations: University Of Utah Health, Salt Lake City, Utah
Conditions: Lung Cancer
Register for Updates
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485
Recruiting
FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
12/21/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Low-grade Glioma, Advanced Solid Tumor
Register for Updates
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
NCT05661461
Recruiting
This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: START Mountain Region, West Valley City, Utah
Conditions: Tumor, Solid, Tumor, Advanced Solid Tumor
Register for Updates
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
NCT03567889
Recruiting
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Huntsman Cancer Institute, University of Utah 2000 Circle of Hope, Salt Lake City, Utah
Conditions: Melanoma Stage IIIB/C
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Wasatch Peak Family Practice, Layton, Utah
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Time Restricted Eating (TRE) Among Endometrial Cancer Patients
NCT04783467
Recruiting
The long-term goal of this study is to determine the efficacy of Time Restricted Eating (TRE) for improving metabolic health, preventing cardiometabolic comorbidities, and improving prognosis after endometrial cancer diagnosis. The primary objective of the protocol is to conduct a 16-week randomized dietary crossover study to evaluate the feasibility, fidelity and preliminary acceptability of TRE among endometrial cancer patients, and to provide proof of principle that TRE can improve metabolic... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Endometrial Cancer
Register for Updates
Pediatric Vasculitis Initiative
NCT02006134
Recruiting
Childhood chronic vasculitis describes a group of rare life-threatening diseases that have in common inflammation of blood vessels in vital organs such as kidneys, lungs and brain. Most knowledge about them comes from adult patients. Severe disease requires aggressive life-saving treatments with steroids and some cancer drugs which can themselves cause damage, and increase risks of cancer and severe infections. Conversely, milder disease can be treated with less toxic drugs. Different classifica... Read More
Gender:
ALL
Ages:
20 years and below
Trial Updated:
11/27/2023
Locations: University of Utah / Primary Children's Hospital, Salt Lake City, Utah
Conditions: Wegeners Granulomatosis (Granulomatosis With Polyangiitis), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Primary CNS Vasculitis, Unclassified Vasculitis, Eosinophilic Granulomatosis With Polyangiitis
Register for Updates
RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring
NCT05292209
Recruiting
Atrial fibrillation (AF) is a growing clinical problem.1 AF is a highly dynamic condition involving episodes of sinus rhythm interspersed with periods of arrhythmia, becoming more difficult to terminate over time. AF carries a substantial cost, morbidity and mortality burden. There are two important approaches to the management of AF: 1). Controlling ventricular response rate without attempting to terminate or prevent AF (rate control), and 2). Attempting to control and maintain sinus rhythm (rh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Atrial Fibrillation Paroxysmal
Register for Updates
A Prospective Analysis of Long-Term Clinical Outcomes and 3D Spine Growth in Anterior Vertebral Body Tethering
NCT04914507
Recruiting
Anterior vertebral body tethering (AVBT) is a novel, minimally invasive, growth modulation technique that was recently approved by the FDA under a Humanitarian Device Exemption (HDE). The goal of AVBT is to control curve progression by applying compression on the convex side of the spine deformity. While there has been great initial enthusiasm about the technique as an alternate treatment option to spinal fusion for skeletally immature children with scoliosis, there is a need to better understan... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
11/14/2023
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Scoliosis Idiopathic
Register for Updates
Hand Sanitizer Use for Herpes Simplex Virus-1
NCT06135844
Recruiting
The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2023
Locations: Cotton Creek Dental, Saint George, Utah
Conditions: Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis
Register for Updates
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745
Recruiting
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
Register for Updates
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
NCT06126042
Recruiting
This is a randomised, double-blind, single dose, parallel groups study to compare the PK, immunogenicity, and safety of 3 abatacept products (DRL_AB, RP and RMP) in male NHV.
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
11/08/2023
Locations: ICON, Salt Lake City, Utah
Conditions: Rheumatoid Arthritis
Register for Updates